Does the media prefer IMMX or LEGN?

In the previous week, Immix Biopharma had 16 more articles in the media than Legend Biotech. MarketBeat recorded 24 mentions for Immix Biopharma and 8 mentions for Legend Biotech. Immix Biopharma's average media sentiment score of 0.38 beat Legend Biotech's score of 0.33 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 6 Very Positive mention(s) 1 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, ELVN or IMMX?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Immix Biopharma N/A N/A -$29.44M -$0.88 N/A

Is ELVN or IMMX more profitable?

Enliven Therapeutics' return on equity of -18.55% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -18.55% -18.09% Immix Biopharma N/A -38.44% -34.72%

Does the media prefer ELVN or IMMX?

In the previous week, Immix Biopharma had 20 more articles in the media than Enliven Therapeutics. MarketBeat recorded 24 mentions for Immix Biopharma and 4 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.12 beat Immix Biopharma's score of 0.38 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 6 Very Positive mention(s) 1 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IMMX or IDYA?

In the previous week, Immix Biopharma had 22 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 24 mentions for Immix Biopharma and 2 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.42 beat Immix Biopharma's score of 0.38 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 6 Very Positive mention(s) 1 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VCYT or IMMX?

In the previous week, Immix Biopharma had 17 more articles in the media than Veracyte. MarketBeat recorded 24 mentions for Immix Biopharma and 7 mentions for Veracyte. Immix Biopharma's average media sentiment score of 0.38 beat Veracyte's score of 0.08 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Immix Biopharma 6 Very Positive mention(s) 1 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMMX or DNLI more profitable?

Immix Biopharma's return on equity of -38.44% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -38.44% -34.72% Denali Therapeutics N/A -55.27% -44.24%

Does the media favor IMMX or DNLI?

In the previous week, Immix Biopharma had 22 more articles in the media than Denali Therapeutics. MarketBeat recorded 24 mentions for Immix Biopharma and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.45 beat Immix Biopharma's score of 0.38 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 6 Very Positive mention(s) 1 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Immix Biopharma (IMMX) Competitors

$9.68 -0.55 (-5.38%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$9.74 +0.05 (+0.57%)

As of 10/2/2026 07:31 PM Eastern

Compare

IMMX vs. LEGN, ELVN, IDYA, VCYT, and DNLI

Should you buy Immix Biopharma stock or one of its competitors? Immix Biopharma's main competitors and comparable companies include Legend Biotech (LEGN), Enliven Therapeutics (ELVN), IDEAYA Biosciences (IDYA), Veracyte (VCYT), and Denali Therapeutics (DNLI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immix Biopharma compare to Legend Biotech?

Immix Biopharma (NASDAQ:IMMX) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Immix Biopharma has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A
Legend Biotech	$1.03B	3.50	-$296.80M	-$0.25	N/A

In the previous week, Immix Biopharma had 16 more articles in the media than Legend Biotech. MarketBeat recorded 24 mentions for Immix Biopharma and 8 mentions for Legend Biotech. Immix Biopharma's average media sentiment score of 0.38 beat Legend Biotech's score of 0.33 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	6 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Legend Biotech	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Immix Biopharma currently has a consensus price target of $24.14, suggesting a potential upside of 149.41%. Legend Biotech has a consensus price target of $55.79, suggesting a potential upside of 200.41%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53

Immix Biopharma has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

Immix Biopharma has a net margin of 0.00% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-38.44%	-34.72%
Legend Biotech	-7.21%	-8.71%	-5.40%

Summary

Legend Biotech beats Immix Biopharma on 8 of the 15 factors compared between the two stocks.

How does Immix Biopharma compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Immix Biopharma (NASDAQ:IMMX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Enliven Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

In the previous week, Immix Biopharma had 20 more articles in the media than Enliven Therapeutics. MarketBeat recorded 24 mentions for Immix Biopharma and 4 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.12 beat Immix Biopharma's score of 0.38 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	6 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enliven Therapeutics' return on equity of -18.55% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Immix Biopharma	N/A	-38.44%	-34.72%

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 30.3% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Enliven Therapeutics presently has a consensus target price of $74.44, suggesting a potential upside of 58.49%. Immix Biopharma has a consensus target price of $24.14, suggesting a potential upside of 149.41%. Given Immix Biopharma's higher probable upside, analysts clearly believe Immix Biopharma is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Enliven Therapeutics and Immix Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Immix Biopharma compare to IDEAYA Biosciences?

Immix Biopharma (NASDAQ:IMMX) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

In the previous week, Immix Biopharma had 22 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 24 mentions for Immix Biopharma and 2 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.42 beat Immix Biopharma's score of 0.38 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	6 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immix Biopharma has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A
IDEAYA Biosciences	$218.71M	15.01	-$113.70M	-$1.94	N/A

Immix Biopharma has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

Immix Biopharma has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-38.44%	-34.72%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

Immix Biopharma presently has a consensus price target of $24.14, indicating a potential upside of 149.41%. IDEAYA Biosciences has a consensus price target of $52.69, indicating a potential upside of 41.04%. Given Immix Biopharma's higher probable upside, equities analysts plainly believe Immix Biopharma is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Immix Biopharma beats IDEAYA Biosciences on 8 of the 15 factors compared between the two stocks.

How does Immix Biopharma compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Immix Biopharma (NASDAQ:IMMX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Veracyte has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Veracyte has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$561.90M	6.55	$66.35M	$1.41	32.49
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

Veracyte has a net margin of 20.37% compared to Immix Biopharma's net margin of 0.00%. Veracyte's return on equity of 9.26% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Immix Biopharma	N/A	-38.44%	-34.72%

Veracyte presently has a consensus target price of $55.78, suggesting a potential upside of 21.76%. Immix Biopharma has a consensus target price of $24.14, suggesting a potential upside of 149.41%. Given Immix Biopharma's higher possible upside, analysts plainly believe Immix Biopharma is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Immix Biopharma had 17 more articles in the media than Veracyte. MarketBeat recorded 24 mentions for Immix Biopharma and 7 mentions for Veracyte. Immix Biopharma's average media sentiment score of 0.38 beat Veracyte's score of 0.08 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immix Biopharma	6 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.3% of Immix Biopharma shares are owned by institutional investors. 1.6% of Veracyte shares are owned by company insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Veracyte beats Immix Biopharma on 10 of the 16 factors compared between the two stocks.

How does Immix Biopharma compare to Denali Therapeutics?

Immix Biopharma (NASDAQ:IMMX) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Immix Biopharma has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

Immix Biopharma has higher earnings, but lower revenue than Denali Therapeutics. Immix Biopharma is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A
Denali Therapeutics	$3.60M	887.05	-$512.54M	-$2.84	N/A

In the previous week, Immix Biopharma had 22 more articles in the media than Denali Therapeutics. MarketBeat recorded 24 mentions for Immix Biopharma and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.45 beat Immix Biopharma's score of 0.38 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	6 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Immix Biopharma's return on equity of -38.44% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-38.44%	-34.72%
Denali Therapeutics	N/A	-55.27%	-44.24%

Immix Biopharma currently has a consensus target price of $24.14, suggesting a potential upside of 149.41%. Denali Therapeutics has a consensus target price of $35.85, suggesting a potential upside of 79.23%. Given Immix Biopharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Immix Biopharma is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Immix Biopharma beats Denali Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Immix Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMMX vs. The Competition

Export

Metric	Immix Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$692.50M	$3.87B	$7.14B	$13.18B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	-11.00	13.06	275.68	26.04
Price / Sales	N/A	1,401.36	661.92	103.09
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	5.47	16.63	10.93	6.31
Net Income	-$29.44M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-11.76%	-2.99%	-2.00%	-1.66%
1 Month Performance	-30.01%	-10.60%	-6.15%	-4.50%
1 Year Performance	369.90%	19.44%	7.44%	2.06%

Immix Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMMX Immix Biopharma	3.1119 of 5 stars	$9.68 -5.4%	$24.14 +149.4%	+361.0%	$692.50M	N/A	N/A	21	Analyst Forecast
LEGN Legend Biotech	3.5714 of 5 stars	$18.45 -1.0%	$53.14 +188.0%	-42.5%	$3.61B	$1.27B	N/A	2,965	News Coverage Insider Trade
ELVN Enliven Therapeutics	2.9141 of 5 stars	$46.09 -4.4%	$75.00 +62.7%	+135.8%	$3.53B	N/A	N/A	67	Analyst Forecast
IDYA IDEAYA Biosciences	3.2026 of 5 stars	$37.46 -5.7%	$52.69 +40.7%	+37.4%	$3.49B	$234.13M	N/A	145	High Trading Volume
VCYT Veracyte	4.0031 of 5 stars	$43.82 +1.1%	$55.78 +27.3%	+28.6%	$3.49B	$517.15M	31.08	755

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMMX) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immix Biopharma (IMMX) Competitors

IMMX vs. LEGN, ELVN, IDYA, VCYT, and DNLI

How does Immix Biopharma compare to Legend Biotech?

Summary

How does Immix Biopharma compare to Enliven Therapeutics?

Summary

How does Immix Biopharma compare to IDEAYA Biosciences?

Summary

How does Immix Biopharma compare to Veracyte?

Summary

How does Immix Biopharma compare to Denali Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX vs. The Competition

Immix Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immix Biopharma (IMMX) Competitors

IMMX vs. LEGN, ELVN, IDYA, VCYT, and DNLI

How does Immix Biopharma compare to Legend Biotech?

Which has preferable earnings and valuation, IMMX or LEGN?

Does the media prefer IMMX or LEGN?

Do insiders & institutionals hold more shares of IMMX or LEGN?

Do analysts recommend IMMX or LEGN?

Which has more risk & volatility, IMMX or LEGN?

Is IMMX or LEGN more profitable?

Summary

How does Immix Biopharma compare to Enliven Therapeutics?

Which has more volatility and risk, ELVN or IMMX?

Which has higher earnings & valuation, ELVN or IMMX?

Does the media prefer ELVN or IMMX?

Is ELVN or IMMX more profitable?

Do institutionals and insiders hold more shares of ELVN or IMMX?

Do analysts prefer ELVN or IMMX?

Summary

How does Immix Biopharma compare to IDEAYA Biosciences?

Does the media favor IMMX or IDYA?

Which has better valuation and earnings, IMMX or IDYA?

Which has more volatility and risk, IMMX or IDYA?

Is IMMX or IDYA more profitable?

Do analysts recommend IMMX or IDYA?

Do institutionals & insiders believe in IMMX or IDYA?

Summary

How does Immix Biopharma compare to Veracyte?

Which has more volatility & risk, VCYT or IMMX?

Which has better valuation and earnings, VCYT or IMMX?

Is VCYT or IMMX more profitable?

Do analysts prefer VCYT or IMMX?

Does the media prefer VCYT or IMMX?

Do insiders and institutionals have more ownership in VCYT or IMMX?

Summary

How does Immix Biopharma compare to Denali Therapeutics?

Which has more risk & volatility, IMMX or DNLI?

Which has higher earnings & valuation, IMMX or DNLI?

Does the media favor IMMX or DNLI?

Do institutionals and insiders hold more shares of IMMX or DNLI?

Is IMMX or DNLI more profitable?

Do analysts prefer IMMX or DNLI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX vs. The Competition

Immix Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools